PRO Alert Digest â€” October 13, 2025

Summary of today's articles:
- 67% of patients completed assessments, reducing discontinuation risk by 30%
- EQ-5D-5 L and MLHFQ predictive of all-cause mortality in ATTR-CM patients
- 67% completion rate achieved through tailored reminders, improving trial retention

ðŸ“Š Cross-Article Insights:
- IMPLEMENTATION PATTERN: 2 articles mention automated reminders as tactical approach

Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications
  https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391
    - **KEY FINDING**: 67% of patients completed assessments, reducing discontinuation risk by 30%.
    - **TACTICAL WIN [SHIP NOW]**: Integrate AI-driven prompts to optimize timing and format for higher engagement.
    - **MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: Growing adoption of digital PRO platforms as standards in oncology trials.
    - **CONCERN**: Limited validation studies raise questions about cross-platform clinical validity.

Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC
  https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204
    - **KEY FINDING**: EQ-5D-5 L and MLHFQ predictive of all-cause mortality in ATTR-CM patients.
    - **TACTICAL WIN [SHIP NOW]**: Integrate auto-reminders to improve PRO completion rates in trials.
    - **MARKET SIGNAL [ðŸ”´ URGENT]**: FDA prioritizing PRO data for faster approval in heart failure and amyloid cardiomyopathy trials.
    - **CONCERN**: Self-selection bias may limit clinical validity of patient-reported outcomes.

Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer
  https://ascopubs.org/doi/10.1200/OA-25-00051
    - **KEY FINDING**: 67% completion rate achieved through tailored reminders, improving trial retention.
    - **TACTICAL WIN [SHIP NOW]**: Integrate AI-driven adaptive questionnaires to reduce burden and enhance engagement.
    - **MARKET SIGNAL [ðŸ”´ URGENT]**: EU mandates PRO integration in all clinical trials by 2025 for faster approvals.
    - **CONCERN**: Limited accessibility may exclude certain demographics, affecting overall study validity.
